Division of Infectious Diseases, Icahn School of Medicine, New York, NY, 10029-5674, USA.
Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY, 10065, USA.
F1000Res. 2021 Jun 28;10:507. doi: 10.12688/f1000research.28327.2. eCollection 2021.
Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics. The significant morbidity and mortality associated with these pathogens bespeaks the urgent need for novel safe and effective therapeutics. This review highlights promising investigational antifungal agents in clinical phases of development: fosmanogepix, ibrexafungerp, rezafungin, encochleated amphotericin B, oteseconazole (VT-1161), VT-1598, PC945, and olorofim. We discuss three first-in-class members of three novel antifungal classes, as well as new agents within existing antifungal classes with improved safety and tolerability profiles due to enhanced pharmacokinetic and pharmacodynamic properties.
由于耐药酵母和霉菌引起的侵袭性真菌病是一个重要且日益严重的公共卫生威胁，这可能是由于免疫抑制宿主的数量不断增加、抗真菌药物耐药性的增加以及实验室诊断技术的改进所致。这些病原体所带来的巨大发病率和死亡率表明，迫切需要新型安全有效的治疗方法。本综述重点介绍了处于临床开发阶段的有前途的抗真菌药物：fosmanogepix、ibrexafungerp、rezafungin、包裹两性霉素 B、oteseconazole（VT-1161）、VT-1598、PC945 和 olorofim。我们讨论了三种新型抗真菌药物类别中的三种首创成员，以及由于增强的药代动力学和药效学特性而具有改善的安全性和耐受性的现有抗真菌药物类别中的新型药物。
